Nuvation Bio Inc. Increase (Decrease) in Interest and Dividends Receivable
Nuvation Bio Inc. (NUVB) reported Increase (Decrease) in Interest and Dividends Receivable of $603.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestAndDividendsReceivable · last filed 2026-08-06
- Nuvation Bio Inc. increase (decrease) in interest and dividends receivable for the quarter ending 2026-06-30 was $627.00K.
- Nuvation Bio Inc. increase (decrease) in interest and dividends receivable for the quarter ending 2026-03-31 was -$24.00K, a 101.62% decline year-over-year.
- Nuvation Bio Inc. increase (decrease) in interest and dividends receivable for the quarter ending 2025-12-31 was -$2.24M.
- Nuvation Bio Inc. increase (decrease) in interest and dividends receivable for the quarter ending 2025-09-30 was $1.54M, a 529.80% increase year-over-year.
- Nuvation Bio Inc. increase (decrease) in interest and dividends receivable for fiscal 2025 was -$285.00K.
- Nuvation Bio Inc. increase (decrease) in interest and dividends receivable for fiscal 2024 was -$132.00K, a 110.85% decline from fiscal 2023.
- Nuvation Bio Inc. increase (decrease) in interest and dividends receivable for fiscal 2023 was $1.22M.
- Nuvation Bio Inc. increase (decrease) in interest and dividends receivable for fiscal 2022 was -$554.00K, a 128.45% decline from fiscal 2021.
| Period end | Increase (Decrease) in Interest and Dividends Receivable 3 month | Increase (Decrease) in Interest and Dividends Receivable 6 month | Increase (Decrease) in Interest and Dividends Receivable 6 month as first filed | Increase (Decrease) in Interest and Dividends Receivable 9 month | Increase (Decrease) in Interest and Dividends Receivable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $627.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $603.00K 10-Q · filed 2026-08-06 | -$1.64M derived: sum of 3 quarters · filed 2026-08-06 | -$96.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$24.00K 10-Q · filed 2026-05-04 | -$2.27M derived: sum of 2 quarters · filed 2026-05-04 | -$723.00K derived: sum of 3 quarters · filed 2026-05-04 | -$1.79M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$699.00K derived: sum of 2 quarters · filed 2026-03-02 | -$1.77M derived: sum of 3 quarters · filed 2026-08-06 | -$285.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $474.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.96M 10-Q · filed 2025-11-03 | $1.39M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $414.00K 10-Q · filed 2026-08-06 | -$155.00K derived: sum of 3 quarters · filed 2026-08-06 | $90.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $1.48M 10-Q · filed 2026-05-04 | $914.00K derived: sum of 2 quarters · filed 2026-05-04 | $1.16M derived: sum of 3 quarters · filed 2026-05-04 | $770.00K derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | -$569.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$324.00K derived: sum of 2 quarters · filed 2026-03-02 | -$713.00K derived: sum of 3 quarters · filed 2026-03-02 | -$132.00K 10-K · filed 2026-03-02 | |
| 2024-09-30 | $245.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$144.00K derived: sum of 2 quarters · filed 2025-11-03 | $437.00K 10-Q · filed 2025-11-03 | $1.11M derived: sum of 4 quarters · filed 2025-11-03 | |
| 2024-06-30 | -$389.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $192.00K 10-Q · filed 2025-08-07 | $861.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.10M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $581.00K 10-Q · filed 2025-05-07 | $1.25M derived: sum of 2 quarters · filed 2025-05-07 | $1.49M derived: sum of 3 quarters · filed 2025-05-07 | $2.01M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | $669.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $907.00K derived: sum of 2 quarters · filed 2025-03-06 | $1.43M derived: sum of 3 quarters · filed 2025-03-06 | $1.22M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $238.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $760.00K derived: sum of 2 quarters · filed 2024-11-06 | $548.00K 10-Q · filed 2024-11-06 | $683.00K derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $522.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $310.00K 10-Q · filed 2024-08-05 | $445.00K derived: sum of 3 quarters · filed 2024-08-05 | $127.00K derived: sum of 4 quarters · filed 2024-08-05 | |
| 2023-03-31 | -$212.00K 10-Q · filed 2024-05-14 | -$77.00K derived: sum of 2 quarters · filed 2024-05-14 | -$395.00K derived: sum of 3 quarters · filed 2024-05-14 | -$220.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$183.00K derived: sum of 2 quarters · filed 2024-02-29 | -$8.00K derived: sum of 3 quarters · filed 2024-02-29 | -$554.00K 10-K · filed 2024-02-29 | |
| 2022-09-30 | -$318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$143.00K derived: sum of 2 quarters · filed 2023-11-02 | -$689.00K 10-Q · filed 2023-11-02 | $536.00K derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | $175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$371.00K 10-Q · filed 2023-08-03 | $854.00K derived: sum of 3 quarters · filed 2023-08-03 | $671.00K derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | -$546.00K 10-Q · filed 2023-05-04 | $679.00K derived: sum of 2 quarters · filed 2023-05-04 | $496.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.48M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.04M derived: sum of 2 quarters · filed 2023-03-15 | $2.02M derived: sum of 3 quarters · filed 2023-03-15 | $1.95M 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $799.00K derived: sum of 2 quarters · filed 2022-11-03 | $722.00K 10-Q · filed 2022-11-03 | $1.38M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $982.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $905.00K 10-Q · filed 2022-08-04 | -$905.00K 10-Q · filed 2021-08-12 | $1.56M derived: sum of 3 quarters · filed 2022-08-04 | $1.04M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$77.00K 10-Q · filed 2022-05-09 | $577.00K derived: sum of 2 quarters · filed 2022-05-09 | $59.00K derived: sum of 3 quarters · filed 2022-05-09 | $477.00K derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $654.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $136.00K derived: sum of 2 quarters · filed 2022-02-28 | $554.00K derived: sum of 3 quarters · filed 2022-02-28 | $264.00K 10-K · filed 2022-02-28 | |
| 2020-09-30 | -$518.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$100.00K derived: sum of 2 quarters · filed 2021-11-10 | -$390.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $418.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $128.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$290.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |